EA201001529A1 - Способ и композиция для лечения mif-опосредованных расстройств - Google Patents
Способ и композиция для лечения mif-опосредованных расстройствInfo
- Publication number
- EA201001529A1 EA201001529A1 EA201001529A EA201001529A EA201001529A1 EA 201001529 A1 EA201001529 A1 EA 201001529A1 EA 201001529 A EA201001529 A EA 201001529A EA 201001529 A EA201001529 A EA 201001529A EA 201001529 A1 EA201001529 A1 EA 201001529A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mif
- treatment
- mediated disorders
- composition
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3838108P | 2008-03-20 | 2008-03-20 | |
| US3937108P | 2008-03-25 | 2008-03-25 | |
| US4580708P | 2008-04-17 | 2008-04-17 | |
| US12109508P | 2008-12-09 | 2008-12-09 | |
| PCT/US2009/037887 WO2009117710A2 (en) | 2008-03-20 | 2009-03-20 | Methods of treating inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201001529A1 true EA201001529A1 (ru) | 2011-06-30 |
Family
ID=41091567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201001529A EA201001529A1 (ru) | 2008-03-20 | 2009-03-20 | Способ и композиция для лечения mif-опосредованных расстройств |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20110262386A1 (https=) |
| EP (2) | EP2252318A4 (https=) |
| JP (2) | JP2011515416A (https=) |
| KR (1) | KR20110014141A (https=) |
| CN (2) | CN102046199A (https=) |
| AU (2) | AU2009225385A1 (https=) |
| BR (1) | BRPI0910259A2 (https=) |
| CA (2) | CA2717071A1 (https=) |
| CO (1) | CO6300848A2 (https=) |
| EA (1) | EA201001529A1 (https=) |
| IL (1) | IL207752A0 (https=) |
| MX (1) | MX2010010198A (https=) |
| NZ (1) | NZ588033A (https=) |
| WO (2) | WO2009117706A2 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ588033A (en) * | 2008-03-20 | 2012-11-30 | Carolus Therapeutics Inc | Methods of treating a mif-mediated disorder |
| US20110070184A1 (en) * | 2008-03-24 | 2011-03-24 | Carolus Therpeutics, Inc. | Methods and compositions for treating atherosclerosis and related condidtions |
| WO2010056910A2 (en) * | 2008-11-12 | 2010-05-20 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
| CN102725311A (zh) * | 2009-09-23 | 2012-10-10 | 卡罗勒斯治疗公司 | 治疗发炎的方法 |
| EP2308485A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Sulfonamides for the prevention of diabetes |
| EP2308484A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
| WO2012125680A1 (en) | 2011-03-16 | 2012-09-20 | Novartis Ag | Methods of treating vasculitis using an il-17 binding molecule |
| WO2012142498A2 (en) * | 2011-04-13 | 2012-10-18 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
| TWI407964B (zh) * | 2011-05-10 | 2013-09-11 | Univ Fu Jen Catholic | 干擾性核糖核酸用於治療或減緩疼痛之用途 |
| EP2723380B1 (en) | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| US10596233B2 (en) | 2011-06-30 | 2020-03-24 | Dignity Health | Use of pertussis toxin as a therapeutic agent |
| WO2013003786A1 (en) * | 2011-06-30 | 2013-01-03 | Dignity Health | Use of pertussis toxin as a therapeutic agent |
| WO2013010955A1 (en) | 2011-07-15 | 2013-01-24 | Morphosys Ag | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
| CN102357249A (zh) * | 2011-10-26 | 2012-02-22 | 广州赫尔氏药物开发有限公司 | 能够抑制耐药性结核杆菌的药物 |
| AU2013255050B2 (en) | 2012-05-01 | 2016-07-28 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US10561676B2 (en) * | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| EP3052526A4 (en) | 2013-10-03 | 2017-04-19 | Oregon Health & Science University | Recombinant polypeptides comprising mhc class ii 1 domains |
| ES2924394T3 (es) * | 2015-01-09 | 2022-10-06 | Adalta Ltd | Moléculas de unión a CXCR4 |
| TW201718851A (zh) * | 2015-09-18 | 2017-06-01 | 通用醫院公司 | 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途 |
| CN109069426B (zh) * | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| CA3008279A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN113893252A (zh) | 2016-03-11 | 2022-01-07 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| KR102645432B1 (ko) * | 2016-03-28 | 2024-03-11 | (주)아모레퍼시픽 | 피부 세포 분화 촉진용 조성물 및 피부 세포 분화 촉진 물질의 스크리닝 방법 |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3445402A4 (en) * | 2016-04-21 | 2019-12-11 | The Board Of Regents Of The University Of Texas System | METHOD AND COMPOSITIONS FOR DETECTING ANEURYSMS |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| EP3472129A4 (en) | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| US11291641B2 (en) * | 2016-10-03 | 2022-04-05 | The Children's Medical Center Corporation | Prevention and treatment of diabetic nephropathy |
| CN108355133A (zh) * | 2017-01-26 | 2018-08-03 | 中国医学科学院阜外医院 | 靶向cxcr7的药物组合物和方法 |
| US11767564B2 (en) * | 2017-10-27 | 2023-09-26 | Board Of Regents, The University Of Texas System | Use of SDHA as a prognostic marker and therapeutic target in uveal melanoma |
| CN107964045B (zh) * | 2017-12-18 | 2021-04-23 | 南京医科大学 | 一种人鼠嵌合抗CXCR2全分子IgG及其应用 |
| BR112020020930A2 (pt) | 2018-04-11 | 2021-03-02 | Ohio State Innovation Foundation | composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit |
| US11679146B2 (en) | 2018-06-05 | 2023-06-20 | Anji Pharmaceuticals Inc. | Compositions and methods for treating pancreatitis |
| EP3802595A1 (en) * | 2018-06-07 | 2021-04-14 | OncoOne Research & Development GmbH | Anti-oxmif/anti-cd3 antibody for cancer treatment |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| WO2020139620A1 (en) * | 2018-12-26 | 2020-07-02 | Colgate-Palmolive Company | Biomarkers of neutrophil deregulation as diagnostic for gingivitis |
| CN110133306B (zh) * | 2019-05-09 | 2023-04-07 | 北京勤邦生物技术有限公司 | 检测西马特罗的酶联免疫试剂盒及其应用 |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
| JP2023517616A (ja) * | 2020-03-11 | 2023-04-26 | バイオラインアールエックス・リミテッド | 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤 |
| WO2021219495A1 (en) * | 2020-04-28 | 2021-11-04 | Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch | Methods for treating or preventing a viral infection or inhibiting viral replication |
| WO2022087719A1 (en) * | 2020-10-28 | 2022-05-05 | University Health Network | Methods of treating spondyloarthritis or symptoms thereof |
| CN117098848A (zh) * | 2021-03-22 | 2023-11-21 | 科列普斯生物医药科技有限公司 | 新型耻垢分枝杆菌重组菌株及其应用 |
| CA3214688A1 (en) | 2021-04-08 | 2022-10-13 | Andrzej KROLEWSKI | Methods of diagnosing and predicting renal decline |
| KR102561554B1 (ko) * | 2021-04-14 | 2023-07-28 | 부산대학교 산학협력단 | 치주질환 진단용 바이오마커 조성물, 치주질환 치료 효용성 평가용 바이오마커 조성물 및 이를 이용한 진단키트 |
| WO2023150294A2 (en) * | 2022-02-04 | 2023-08-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of detecting and treating cerebral aneurysms |
| WO2025171411A1 (en) * | 2024-02-09 | 2025-08-14 | Herophilus, Inc. | Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions |
| CN121714692A (zh) * | 2026-02-26 | 2026-03-24 | 华中科技大学同济医学院附属协和医院 | Cxcl14抑制剂在制备用于预防或治疗患者腹主动脉瘤的药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4708510B2 (ja) * | 1993-05-17 | 2011-06-22 | サイトカイン ファーマサイエンシズ，インコーポレーテッド | サイトカイン媒介毒性に関係する疾患の治療における遊走阻止因子の抑制 |
| US6645493B1 (en) * | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
| US7312318B2 (en) * | 2002-03-01 | 2007-12-25 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
| US20070072861A1 (en) * | 2000-03-27 | 2007-03-29 | Barbara Roniker | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders |
| EP1465660A4 (en) * | 2001-01-12 | 2005-09-21 | Cytokine Pharmasciences Inc | METHOD AND COMPOSITIONS FOR MODULATING THE REGULATION OF THE CYTOTOXIC LYMPHOCYTE RESPONSE BY MACROPHAGE MIGRATION HEMM FACTOR |
| JP2003226653A (ja) * | 2001-11-30 | 2003-08-12 | Jun Nishihira | 多発性硬化症治療剤 |
| WO2003047622A1 (fr) * | 2001-11-30 | 2003-06-12 | Jun Nishihira | Remedes pour la sclerose en plaques |
| US6656168B2 (en) * | 2001-12-18 | 2003-12-02 | Kimberly-Clark Worldwide, Inc. | Feminine care product with discrete areas of a skin wellness additive |
| WO2003072753A2 (en) * | 2002-02-27 | 2003-09-04 | Emory University | Multimeric binding complexes |
| EP1569692B1 (en) * | 2002-11-25 | 2010-11-10 | Jallal Messadek | Betaine and salicylic acid compositions |
| TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| US20050202010A1 (en) * | 2003-08-29 | 2005-09-15 | Giroir Brett P. | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
| US7897349B2 (en) * | 2003-12-30 | 2011-03-01 | The United States Of America As Represented By The Department Of Veterans Affairs | Macrophage migration inhibitory factor (MIF) as marker for urological inflammatory disease |
| WO2006105666A1 (en) * | 2005-04-06 | 2006-10-12 | Queen's University At Kingston | Administration of macrophage targeted formulations of compounds which modulate cholesterol-metabolizing enzymes for treatment of atherosclerosis |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JPWO2007138961A1 (ja) * | 2006-05-29 | 2009-10-08 | レドックス・バイオサイエンス株式会社 | マクロファージ遊走阻止因子阻害剤 |
| NZ588033A (en) * | 2008-03-20 | 2012-11-30 | Carolus Therapeutics Inc | Methods of treating a mif-mediated disorder |
| US20110070184A1 (en) * | 2008-03-24 | 2011-03-24 | Carolus Therpeutics, Inc. | Methods and compositions for treating atherosclerosis and related condidtions |
| WO2010056910A2 (en) * | 2008-11-12 | 2010-05-20 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
| WO2010065491A2 (en) * | 2008-12-01 | 2010-06-10 | Carolus Therapeutics, Inc. | Methods of treating inflammatory disorders |
-
2009
- 2009-03-20 NZ NZ588033A patent/NZ588033A/xx not_active IP Right Cessation
- 2009-03-20 BR BRPI0910259A patent/BRPI0910259A2/pt not_active IP Right Cessation
- 2009-03-20 EA EA201001529A patent/EA201001529A1/ru unknown
- 2009-03-20 EP EP09721240A patent/EP2252318A4/en not_active Withdrawn
- 2009-03-20 US US12/918,964 patent/US20110262386A1/en not_active Abandoned
- 2009-03-20 AU AU2009225385A patent/AU2009225385A1/en not_active Abandoned
- 2009-03-20 KR KR1020107023480A patent/KR20110014141A/ko not_active Withdrawn
- 2009-03-20 CA CA2717071A patent/CA2717071A1/en not_active Abandoned
- 2009-03-20 US US12/918,968 patent/US20110044988A1/en not_active Abandoned
- 2009-03-20 WO PCT/US2009/037883 patent/WO2009117706A2/en not_active Ceased
- 2009-03-20 CN CN200980109905XA patent/CN102046199A/zh active Pending
- 2009-03-20 AU AU2009225389A patent/AU2009225389A1/en not_active Abandoned
- 2009-03-20 JP JP2011501000A patent/JP2011515416A/ja active Pending
- 2009-03-20 MX MX2010010198A patent/MX2010010198A/es active IP Right Grant
- 2009-03-20 JP JP2011501003A patent/JP2011526244A/ja active Pending
- 2009-03-20 CA CA2717365A patent/CA2717365A1/en not_active Abandoned
- 2009-03-20 CN CN2009801093284A patent/CN102088993A/zh active Pending
- 2009-03-20 WO PCT/US2009/037887 patent/WO2009117710A2/en not_active Ceased
- 2009-03-20 EP EP09722541A patent/EP2254597A4/en not_active Withdrawn
-
2010
- 2010-08-23 IL IL207752A patent/IL207752A0/en unknown
- 2010-09-20 CO CO10116141A patent/CO6300848A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2254597A2 (en) | 2010-12-01 |
| JP2011515416A (ja) | 2011-05-19 |
| WO2009117710A2 (en) | 2009-09-24 |
| KR20110014141A (ko) | 2011-02-10 |
| CN102088993A (zh) | 2011-06-08 |
| US20110262386A1 (en) | 2011-10-27 |
| JP2011526244A (ja) | 2011-10-06 |
| WO2009117706A3 (en) | 2010-01-21 |
| CA2717365A1 (en) | 2009-09-24 |
| EP2252318A4 (en) | 2012-04-18 |
| BRPI0910259A2 (pt) | 2015-12-01 |
| CA2717071A1 (en) | 2009-09-24 |
| AU2009225389A1 (en) | 2009-09-24 |
| WO2009117710A3 (en) | 2010-01-21 |
| CN102046199A (zh) | 2011-05-04 |
| EP2252318A2 (en) | 2010-11-24 |
| NZ588033A (en) | 2012-11-30 |
| IL207752A0 (en) | 2010-12-30 |
| EP2254597A4 (en) | 2012-04-18 |
| WO2009117706A2 (en) | 2009-09-24 |
| MX2010010198A (es) | 2010-12-21 |
| US20110044988A1 (en) | 2011-02-24 |
| CO6300848A2 (es) | 2011-07-21 |
| AU2009225385A1 (en) | 2009-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201001529A1 (ru) | Способ и композиция для лечения mif-опосредованных расстройств | |
| EA200802184A1 (ru) | Фармацевтические композиции с ингибиторами dpp iv | |
| MX2012003514A (es) | Metodos para tratamiento de inflamaciones. | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| EA201100609A1 (ru) | Способы лечения воспаления | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| EA201070544A1 (ru) | Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений | |
| UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
| CY1112320T1 (el) | Τιτλοδοτηση της ταπενταδολης | |
| AR056816A1 (es) | Composicion con ácido docosapentenoico | |
| EA201071169A1 (ru) | ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3 | |
| UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
| EA200970251A1 (ru) | Антитела к миостатину | |
| MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
| EA200802166A1 (ru) | Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью | |
| EA200970173A1 (ru) | Химические соединения | |
| PT2222669E (pt) | Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p) | |
| EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| EA200602243A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
| UA107103C2 (uk) | Нікотиновмісні м'які желатинові пастилки | |
| EA201171074A1 (ru) | Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y | |
| EA201170425A1 (ru) | Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения | |
| MX383583B (es) | Composiciones organicas para tratar enfermedades relacionadas con beta-enac. |